My name is Michael Morale. As director of multichannel content for Bionews Services, my job is to bring engaging multimedia content to all of our rare disease communities. I would like to introduce some of the resources available to our Pulmonary Fibrosis News forum members, as well…
Check Out Our Pulmonary Fibrosis News Multimedia Content
Before my mom had a double-lung transplant, my dad was her only caregiver. Holly, my mom, was reasonably independent until a couple of months before being admitted to the ICU. Ed, my dad, was her companion and helper, encouraging her to walk for exercise and helping her…
Processa Pharmaceuticals will explore and further develop the anti-fibrotic, anti-inflammatory compound HT-100 as a potential treatment for rare fibrotic-related diseases in adults, including focal segmental glomerulosclerosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). The company announced that it has acquired the exclusive global rights to develop…
I often write about living with idiopathic pulmonary fibrosis (IPF) and what I’ve lost as a result of my diagnosis. It’s easy to write about because my life has changed drastically over the past three years. But I need to remember that the changes haven’t been all bad.
Protein on Surface of Immune Cells May Drive Inflammation in Pulmonary Fibrosis, Study Suggests
Immune cells can sense the mechanical forces at work in the lungs via a gate called PIEZO1, and deleting this gene in immune cells led to worse lung infections, researchers report. But its loss eased the inflammation associated with lung scarring in a mouse model of pulmonary fibrosis. Their study…
GDF15 Protein May Serve as Biomarker for Identifying IPF Patients with Poor Outcomes, Study Suggests
A protein called GDF15, which is secreted by a type of lung cells, is increased in the lungs and blood of people with idiopathic pulmonary fibrosis, a study shows. Supported by this finding, researchers believe that GDF15 may serve as a biomarker to help identify people who have…
Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest.  Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s co-founder,…
On Independence Day, I found myself alone, drunk, and crying. Every other person at the small party had adjourned to the parking lot to smoke. I have always had a problem with smoking. The first fight my husband, Jonny, and I ever had was when I found out that he…
Patients who take either Esbriet (pirfenidone, sold by Genentech) or Ofev (nintedanib, by Boehringer Ingelheim) — two anti-fibrotic therapies approved to treat idiopathic pulmonary fibrosis — often experience significant gastrointestinal side effects, a Dutch study shows. The study, “Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in…
Over a month ago, I returned from a three-week vacation to Europe. My wife and I were active every day of the trip. Most of our physical activity consisted of walking, but we also went swimming when we had the opportunity. We established a routine in each country we…
Your PF Community
Recommended Posts
- With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients
- How we manage the long commute to my IPF doctor appointments
- In preparing for emergencies, we’re using technology to our advantage
- US, EU regulators name deupirfenidone an orphan drug for treating IPF
- This month is our time to raise awareness about rare diseases
